Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Oliveri

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Lancet (London, England)|October 1, 2013
Enrichment of autologous fat grafts with ex-vivo expanded adipose tissue-derived stem cells for graft survival: a randomised placebo-controlled trialStig-Frederik Trojahn Kølle, Anne Fischer-Nielsen, Anders Bruun Mathiasen, et al.
Journal for Immunotherapy of Cancer|January 8, 2025
Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a studyPeter Hillemanns, Michal Zikan, Frédéric Forget, et al.
Trials|May 11, 2019
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosisAntonio Uccelli, Alice Laroni, Lou Brundin, et al.
International Journal of Radiation Oncology, Biology, Physics|April 22, 2018
Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX)Christian Grønhøj, David H Jensen, Peter Vester-Glowinski, et al.
Lancet (London, England)|September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Rogier Mous, Michael Roost Clausen, et al.
The Lancet. Neurology|October 23, 2021
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trialAntonio Uccelli, Alice Laroni, Rehiana Ali, et al.
Medrxiv : the Preprint Server for Health Sciences|October 14, 2024
Physical therapy in patients with Parkinson's disease treated with Deep Brain Stimulation: a Delphi panel studyM Guidetti, S Marceglia, T Bocci, et al.
Journal of Clinical Microbiology|August 1, 2002
Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida speciesG Morace, G Amato, F Bistoni, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2024
Adaptive Deep Brain Stimulation in Parkinson's Disease: A Delphi Consensus StudyM Guidetti, T Bocci, M De Pedro Del Álamo, et al.
Infection|October 24, 2013
SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patientsM T Montagna, G Lovero, C Coretti, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Lancet (London, England)|October 1, 2013
Enrichment of autologous fat grafts with ex-vivo expanded adipose tissue-derived stem cells for graft survival: a randomised placebo-controlled trialStig-Frederik Trojahn Kølle, Anne Fischer-Nielsen, Anders Bruun Mathiasen, et al.
Journal for Immunotherapy of Cancer|January 8, 2025
Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a studyPeter Hillemanns, Michal Zikan, Frédéric Forget, et al.
Trials|May 11, 2019
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosisAntonio Uccelli, Alice Laroni, Lou Brundin, et al.
International Journal of Radiation Oncology, Biology, Physics|April 22, 2018
Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX)Christian Grønhøj, David H Jensen, Peter Vester-Glowinski, et al.
Lancet (London, England)|September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Rogier Mous, Michael Roost Clausen, et al.
The Lancet. Neurology|October 23, 2021
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trialAntonio Uccelli, Alice Laroni, Rehiana Ali, et al.
Medrxiv : the Preprint Server for Health Sciences|October 14, 2024
Physical therapy in patients with Parkinson's disease treated with Deep Brain Stimulation: a Delphi panel studyM Guidetti, S Marceglia, T Bocci, et al.
Journal of Clinical Microbiology|August 1, 2002
Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida speciesG Morace, G Amato, F Bistoni, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2024
Adaptive Deep Brain Stimulation in Parkinson's Disease: A Delphi Consensus StudyM Guidetti, T Bocci, M De Pedro Del Álamo, et al.
Infection|October 24, 2013
SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patientsM T Montagna, G Lovero, C Coretti, et al.
Pageof 7